These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1485 related items for PubMed ID: 16024750

  • 1. Is the estrogen controversy over? Deconstructing the Women's Health Initiative study: a critical evaluation of the evidence.
    Harman SM, Naftolin F, Brinton EA, Judelson DR.
    Ann N Y Acad Sci; 2005 Jun; 1052():43-56. PubMed ID: 16024750
    [Abstract] [Full Text] [Related]

  • 2. Menopause and stroke and the effects of hormonal therapy.
    Lobo RA.
    Climacteric; 2007 Oct; 10 Suppl 2():27-31. PubMed ID: 17882669
    [Abstract] [Full Text] [Related]

  • 3. Hormone replacement therapy in the post-Women's Health Initiative era. Report a a meeting held in Funchal, Madeira, February 24-25, 2003.
    Burger H.
    Climacteric; 2003 May; 6 Suppl 1():11-36. PubMed ID: 12945798
    [Abstract] [Full Text] [Related]

  • 4. Investigative models for determining hormone therapy-induced outcomes in brain: evidence in support of a healthy cell bias of estrogen action.
    Brinton RD.
    Ann N Y Acad Sci; 2005 Jun; 1052():57-74. PubMed ID: 16024751
    [Abstract] [Full Text] [Related]

  • 5. KEEPS: The Kronos Early Estrogen Prevention Study.
    Harman SM, Brinton EA, Cedars M, Lobo R, Manson JE, Merriam GR, Miller VM, Naftolin F, Santoro N.
    Climacteric; 2005 Mar; 8(1):3-12. PubMed ID: 15804727
    [Abstract] [Full Text] [Related]

  • 6. Implications of recent clinical trials of postmenopausal hormone therapy for management of cardiovascular disease.
    Rossouw JE.
    Ann N Y Acad Sci; 2006 Nov; 1089():444-53. PubMed ID: 17261787
    [Abstract] [Full Text] [Related]

  • 7. WHI risks: any relevance to menopause management?
    Burger HG.
    Maturitas; 2007 May 20; 57(1):6-10. PubMed ID: 17368974
    [Abstract] [Full Text] [Related]

  • 8. Hormone replacement therapy and cardioprotection: what is good and what is bad for the cardiovascular system?
    Rosano GM, Vitale C, Fini M.
    Ann N Y Acad Sci; 2006 Dec 20; 1092():341-8. PubMed ID: 17308159
    [Abstract] [Full Text] [Related]

  • 9. The Women's Health Initiative could not have detected cardioprotective effects of starting hormone therapy during the menopausal transition.
    Naftolin F, Taylor HS, Karas R, Brinton E, Newman I, Clarkson TB, Mendelsohn M, Lobo RA, Judelson DR, Nachtigall LE, Heward CB, Hecht H, Jaff MR, Harman SM, Women's Health Initiative.
    Fertil Steril; 2004 Jun 20; 81(6):1498-501. PubMed ID: 15193467
    [Abstract] [Full Text] [Related]

  • 10. Postmenopausal hormones and coronary artery disease: potential benefits and risks.
    Lobo RA.
    Climacteric; 2007 Oct 20; 10 Suppl 2():21-6. PubMed ID: 17882668
    [Abstract] [Full Text] [Related]

  • 11. Indications for hormone therapy: the post-Women's Health Initiative era.
    Reed SD, Newton KM, Lacroix AZ.
    Endocrinol Metab Clin North Am; 2004 Dec 20; 33(4):691-715. PubMed ID: 15501641
    [Abstract] [Full Text] [Related]

  • 12. Recent epidemiological evidence relevant to the clinical management of the menopause.
    Shapiro S.
    Climacteric; 2007 Oct 20; 10 Suppl 2():2-15. PubMed ID: 17882666
    [Abstract] [Full Text] [Related]

  • 13. Postmenopausal hormone therapy: new questions and the case for new clinical trials.
    Manson JE, Bassuk SS, Harman SM, Brinton EA, Cedars MI, Lobo R, Merriam GR, Miller VM, Naftolin F, Santoro N.
    Menopause; 2006 Oct 20; 13(1):139-47. PubMed ID: 16607110
    [Abstract] [Full Text] [Related]

  • 14. Is there a place for postmenopausal hormone therapy use in women with lupus?
    Gompel A, Piette JC.
    Panminerva Med; 2008 Sep 20; 50(3):247-54. PubMed ID: 18927529
    [Abstract] [Full Text] [Related]

  • 15. The Women's Health Initiative trial and related studies: 10 years later: a clinician's view.
    Gurney EP, Nachtigall MJ, Nachtigall LE, Naftolin F.
    J Steroid Biochem Mol Biol; 2014 Jul 20; 142():4-11. PubMed ID: 24172877
    [Abstract] [Full Text] [Related]

  • 16. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation.
    Grodstein F, Manson JE, Stampfer MJ.
    J Womens Health (Larchmt); 2006 Jul 20; 15(1):35-44. PubMed ID: 16417416
    [Abstract] [Full Text] [Related]

  • 17. Invited Commentary: Hormone therapy risks and benefits--The Women's Health Initiative findings and the postmenopausal estrogen timing hypothesis.
    Banks E, Canfell K.
    Am J Epidemiol; 2009 Jul 01; 170(1):24-8. PubMed ID: 19468078
    [Abstract] [Full Text] [Related]

  • 18. Estrogens and cerebrovascular stroke: what do animal models teach us?
    Wise PM.
    Ann N Y Acad Sci; 2005 Jun 01; 1052():225-32. PubMed ID: 16024765
    [Abstract] [Full Text] [Related]

  • 19. The effect of medroxyprogesterone acetate on estrogen-dependent risks and benefits--an attempt to interpret the Women's Health Initiative results.
    Kuhl H, Stevenson J.
    Gynecol Endocrinol; 2006 Jun 01; 22(6):303-17. PubMed ID: 16785155
    [Abstract] [Full Text] [Related]

  • 20. Combined analysis of Women's Health Initiative observational and clinical trial data on postmenopausal hormone treatment and cardiovascular disease.
    Prentice RL, Langer RD, Stefanick ML, Howard BV, Pettinger M, Anderson GL, Barad D, Curb JD, Kotchen J, Kuller L, Limacher M, Wactawski-Wende J, Women's Health Initiative Investigators.
    Am J Epidemiol; 2006 Apr 01; 163(7):589-99. PubMed ID: 16484450
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 75.